| Symbol | SPRC |
|---|---|
| Name | SCISPARC LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 20 RAUL WALLENBERG STREET,TOWER A, 2ND FLOOR, TEL AVIV, 6971916, Israel |
| Telephone | +972 37175777 |
| Fax | — |
| — | |
| Website | https://www.scisparc.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001611746 |
| Description | SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority. Additional info from NASDAQ: |
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
Read more📋 SMITH JAMES EDMOND (10% Stockholder) plans to sell 74K shares of SciSparc Ltd. (at $7.90 each, total $584K) Filed: Jun 22, 2026 | ID: 004797
Read moreSciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
Read moreDirector Shrem Itschak 🔴 sold 462 shares of SciSparc Ltd. (SPRC) at $10.00 Transaction Date: Jun 01, 2026 | Filing ID: 064445
Read moreSciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
Read moreNew Form SCHEDULE 13G/A - SciSparc Ltd. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001213900-26-057795 <b>Size:</b> 7 KB
Read more